Archive | Clinical Trials

Ideaya Biosciences Begins Trial of IDE196, Xalkori in Uveal Melanoma Patients

San Francisco-based Ideaya Biosciences on Tuesday said that it has dosed its first uveal melanoma patient in a clinical trial evaluating its PKC inhibitor IDE196 with Pfizer’s cMET inhibitor crizotinib (Xalkori).

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma

Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, is pleased to announce that 50% of the expected events for the primary outcome analysis of the PIVOTAL study were reached in December 2020.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

World first melanoma success in Australia prompts new trial

A Sydney man who was seriously ill with advanced melanoma has made a remarkable recovery after receiving a drug reserved for breast and ovarian cancer.

Read the full story

Posted in Melanoma News, Health Professionals, Patients, Clinical Trials, Latest News

Sydney man recovers from advanced melanoma in unconventional treatment

A Sydney man has recovered from advanced melanoma thanks to a drug usually used for breast and ovarian cancer, prompting the Melanoma Institute to run a new clinical trial.

Read the full story

Posted in Melanoma News, Health Professionals, Patients, Clinical Trials, Latest News